Ribozymes as Therapeutic Agents: Are We Getting Closer?

An editorial addresses a study by Yamazaki et al in which they extend the utility of ribozymes for target validation in human cancer. A hammerhead ribozyme targeting an aberrantly spliced epidermal growth factor receptor transcript is capable of cleaving its target in vitro.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JNCI : Journal of the National Cancer Institute 1998-04, Vol.90 (8), p.558-559
Hauptverfasser: Scanlon, Kevin J., Kashani-Sabet, Mohammed
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:An editorial addresses a study by Yamazaki et al in which they extend the utility of ribozymes for target validation in human cancer. A hammerhead ribozyme targeting an aberrantly spliced epidermal growth factor receptor transcript is capable of cleaving its target in vitro.
ISSN:0027-8874
1460-2105
DOI:10.1093/jnci/90.8.558